All-trans retinoic acid (ATRA) is a potent differentiating agent for the treatment of acute promyelocytic leukemia (APL). Although ATRA is generally well-tolerated, some patients develop side effects, the most severe of which is ATRA syndrome. We report on a patient with APL who developed isolated nephrotic-range proteinuria during ATRA therapy for remission-induction. ATRA was discontinued and the proteinuria decreased significantly 5 days after dexamethasone treatment. The occurrence of isolated proteinuria during ATRA treatment is a rare adverse event. 
INTRODUCTION
Differentiation therapy with all-trans retinoic acid (ATRA) is currently the first-line treatment for acute promyelocytic leukemia (APL).
1) The administration of ATRA for patients with newly diagnosed APL, either alone or combined with induction chemotherapy, has improved prognosis; specifically, the 2-year event-free survival (EFS) is 79% and the overall survival (OS) is 97%. 2) In addition, ATRA alone or in combination with low-dose chemotherapy given together with ATRA as maintenance therapy appears to have beneficial effects. [3] [4] [5] ATRA is usually well-tolerated by most patients, but a few major side effects have been observed. The most serious known side effect is the ATRA syndrome. The relatively rare side effects of ATRA treatment include Sweet's syndrome, scrotal ulcers, myositis, and myocarditis. [6] [7] [8] We report the case of a patient with APL who developed isolated nephrotic-range proteinuria during ATRA treatment.
CASE REPORT
A 24-year-old man was admitted to our hospital in March 2007 for evaluation of uncontrolled gingival bleeding and fever occurring after a dental procedure. His medical history was significant only for a right inguinal herniorraphy 4 years ago. Laboratory examination on admission revealed a leukocytosis (22.4×10 9 /L), anemia (6.7 g/dL), thrombocytopenia (30×10 9 /L), a coagulopathy with hypofibrinogenemia (44mg/dL), and elevated fibrin degradation products (29.4μg/ dL). The initial blood urea nitrogen and creatinine concentrations were 15.4 and 1.0mg/dL, Dexamethasone was started on day 15; the 24-hour proteinuria then decreased to 12.5g/day. However, the spot urine protein remained ＞300mg/dL and the ATRA was subsequently discontinued on day 22. The concentration of the 24-hour protein decreased gradually. Dexamethasone was discontinued on day 23.
respectively. There was no proteinuria in the initial urinalysis. Bone marrow (BM) examination revealed a hypercellular marrow; the results confirmed APL with a microgranular variant [AMLM3v (WHO classification)]. Cytogenetic analysis showed a t(15;17)(q22;q24) in all metaphases examined. This translocation was also detected in 94% of the BM cells by dual color fluorescence in situ hybridization (FISH) analysis (Fig. 1) . A diagnosis of APL was made and treatment was started with oral ATRA at a dose 45mg/m 2 /day divided into 2 doses, and chemotherapy consisting of intravenous idarubicin (12mg/m 2 ) on days 2, 4, and 6. The patient received empiric antibiotics (cepfiramide, an aminoglycoside, and metronidazole) from the day of admission because of an oral lesion and the fever. Because the fever persisted, the antibiotics were changed to meropenem and teicoplanin on day 4 of hospitalization and the fever subsided.
On day 14 of ATRA therapy, the spot urine showed >300mg/dL of protein. Therefore, we performed a 24-hour urinalysis that revealed a nephrotic-range proteinuria (nephrotic-range: ＞3.5g/ day; patient value: 19.24g/day). Despite the presence of nephrotic-range proteinuria, he had no sign or symptoms of the nephrotic syndrome. At that time, the blood urea nitrogen and creatinine concentrations were 18.0 and 1.0mg/dL, respectively. Viral markers (HIV and hepatitis), syphilis screening, anti-streptolysin O, immunologic markers (immunoglobulin, anti-nuclear antibory, anti-neutrophil cytoplasmic antibody, anti-double strain DNA, C3, and C4), renal imaging of the kidneys, and an abdominal CT were performed, all of which were negative or normal. Although proteinuria is associated with many medications (e.g., non-steroidal anti-inflammatory drugs and rifampin), these medications were not given to this patient. In spite of thorough testing for proteinuria, other clinical evidences of nephritic syndrome were not identified. In addition, there was no increase in the peripheral blood leukocyte count (0.8×10 9 /L), and no dyspnea, fever, weight gain, pulmonary infiltration, or pleural and pericardial effusions, which are frequently associated with ATRA syndrome.
Although proteinuria is not a typical presentation of the ATRA syndrome, treatment with dexamethasone (10mg i.v. q 12 hours) was started on day 15; the 24-hour proteinuria decreased to 12.5g/day. However, the spot urine protein remained >300mg/dL and the ATRA was subsequently discontinued on day 22. The amount of the 24-hour protein decreased gradually and the spot urine protein became negative on day 25, allowing for the re-introduction of ATRA as part of induction therapy on day 27. Dexamethasone was discontinued on day 23 (Fig. 2) . Approximately two months later, the BM examination revealed a complete remission. After the third cycle of ATRA combined consolidation chemotherapy, the patient has remained in complete remission with an urinalysis within normal limits.
DISCUSSION
The ATRA syndrome, also known as retinoic acid syndrome, results from the serious side effects of ATRA-based therapy. Frankel et al. reported the first description of this syndrome in 9 of 35 (25%) newly diagnosed APL patients treated with ATRA. 9) In the absence of strict criteria, the diagnosis of the ATRA syndrome is based on a constellation of findings. It has been suggested that the diagnosis of the ATRA syndrome should be based on the presence of at least three of the following signs and/or symptoms in the absence of alternative explanations: fever, weight gain, respiratory distress, pulmonary infiltrates, pleural or pericardial effusions, hypotension, and renal failure. The ATRA syndrome occurs in 6∼27% of APL patients within 2∼47 days after the initiation of treatment with ATRA and the median time of onset is 7 days after initiation of treatment. 9, 10) Renal dysfunction occurs frequently in patients with APL during ATRA therapy. Renal failure has been reported in 39% of cases of the ATRA syndrome. 10) Renal involvement in the ATRA syndrome may be caused by several mechanisms: endothelial damage-induced hypotension with capillary leakage syndrome and microcirculation obstruction, tissue infiltration by mature lymphocytes that escape from the BM and capillaries due to overexpression of integrins. 11) Cases of isolated acute renal failure have also been described with the ATRA syndrome. The most frequent renal lesion identified is tubular necrosis and renal infiltration by lymphocytes. 12) There have also been cases reported with granulomatous interstitial nephritis and cortical necrosis. 13, 14) However, this is the first report of isolated, massive proteinuria in an APL patient during ATRA treatment, although a case with transitory proteinuria was reported by Miró et al. 15) We did not perform a renal biopsy due to the bleeding and infectious risks; a renal biopsy is a valuable tool in patients with nephrotic-range proteinuria for establishing a definitive diagnosis, guiding therapy, and assessing prognosis. This case was limited to exclude various renal diseases causing nephrotic syndrome, such as minimal hange disease, focal segmental glomerulonephritis, membranous proliferative glomerulonephritis which could be alleviated by glucocorticoid treatment.
In conclusion, we could not identify any other cause of the proteinuria in the patient described herein and therefore, concluded that it would be related to the ATRA treatment, albeit no recurrence of proteinuria after restarting ATRA. Although not the typical ATRA syndrome, the 24-hour proteinuria gradually decreased and was easily reversed with no recurrence after treatment with dexamethasone. 
